Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Clearance of Nasal Staphylococcus Aureus With Triple Antibiotic Ointment

This study has been completed.
Information provided by (Responsible Party):
Dennis West, Northwestern University Identifier:
First received: October 15, 2009
Last updated: December 11, 2014
Last verified: December 2014
Staphylococcus aureus, a bacteria that lives commonly in the anterior nostrils, is seen in about 30% of healthcare workers. Applying mupirocin ointment, a prescription, to the nostrils twice daily for 5 days is the current standard of care for treatment to clear this bacteria. This research study is designed to determine the rate of clearance of this bacteria in healthcare workers who are carriers when using triple antibiotic ointment instead of mupirocin ointment.

Condition Intervention
Nasal Carriers of Staphylococcus Aureus
Drug: Neosporin (polymyxin B 5,000units, bacitracin 400 units, neomycin 3.5mg)

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Clearance of Nasal Staphylococcus Aureus Colonization With Triple Antibiotic Ointment

Resource links provided by NLM:

Further study details as provided by Northwestern University:

Primary Outcome Measures:
  • Carrier Rate for Staphylococcus Aureus [ Time Frame: Baseline ]
    Percentage of subjects with baseline culture positive for Staphylococcus aureus (via nasal swab)

  • MSSA Clearance Rate [ Time Frame: 14 days ]
    Percentage of subjects with methicillin-sensitive S. aureus on Baseline culture who achieved clearance with treatment.

  • MRSA Clearance Rate [ Time Frame: 14 days ]
    Percentage of subjects with methicillin-resistant S. aureus on Baseline culture who achieved clearance with treatment.

Enrollment: 216
Study Start Date: September 2009
Study Completion Date: November 2010
Primary Completion Date: November 2010 (Final data collection date for primary outcome measure)
Intervention Details:
    Drug: Neosporin (polymyxin B 5,000units, bacitracin 400 units, neomycin 3.5mg)
    2 1/32oz packages will be dispensed. If positive nasal swab for S. aureus, subjects will apply a small amount to anterior nares twice daily for 5 days.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Willing and able to give informed consent
  • Must have consented prior to registration for the study

Exclusion Criteria:

  • active infection
  • concurrent treatment with antibiotics, topical or systemic
  • S. aureus decolonization attempt in prior six months
  • history of HIV
  • chemotherapy or systemic immunosuppressive therapy
  • history of neomycin allergy or sensitivity
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00997139

United States, Illinois
Northwestern University
Chicago, Illinois, United States, 60611
Sponsors and Collaborators
Northwestern University
Principal Investigator: Peter Lio, MD Northwestern Unviersity
  More Information

Responsible Party: Dennis West, Professor in Dermatology and Pediatrics, Northwestern University Identifier: NCT00997139     History of Changes
Other Study ID Numbers: NU-9892
Study First Received: October 15, 2009
Results First Received: April 10, 2012
Last Updated: December 11, 2014

Keywords provided by Northwestern University:
staphylococcus aureus

Additional relevant MeSH terms:
Anti-Bacterial Agents
Polymyxin B
Bacitracin zinc, neomycin sulfate, polymyxin B, drug combination
Anti-Infective Agents
Protein Synthesis Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Anti-Infective Agents, Local processed this record on April 28, 2017